Amyloid-beta N-terminal Aβ1–15 epitope region (Aβ1–15)

The Amyloid-beta (Aβ) N-terminal Aβ1–15 epitope region is a specific sequence of the first 15 amino acids of the Aβ peptide, which is generated through the proteolytic processing of the Amyloid Precursor Protein (APP) by β- and γ-secretases (Source 1.1.3, 1.5.1). This region is recognized as the primary B-cell epitope of Aβ and is a major target for disease-modifying therapies in Alzheimer's disease, particularly active vaccines and passive monoclonal antibodies (Source 1.3.1, 1.3.3). While Aβ is central to the amyloid cascade hypothesis due to its tendency to aggregate into neurotoxic oligomers and insoluble plaques, the N-terminal region also possesses physiological roles, including antimicrobial activity and metal ion binding (Source 1.1.4, 1.5.1). Therapeutic strategies targeting this epitope, such as the vaccine ACI-24 and the monoclonal antibody Bapineuzumab, aim to facilitate the clearance of amyloid deposits via microglial phagocytosis or by neutralizing soluble toxic species (Source 1.3.2, 1.3.3). By focusing on the N-terminus, these therapies attempt to avoid the inflammatory T-cell responses associated with earlier full-length Aβ vaccines (Source 1.3.3). However, therapeutic intervention in this region is frequently complicated by safety concerns such as Amyloid-Related Imaging Abnormalities (ARIA), which manifest as brain edema (ARIA-E) or microhemorrhages (ARIA-H) (Source 1.3.1, 1.4.1). Monitoring these effects through neuroimaging and cerebrospinal fluid biomarkers remains essential for evaluating the efficacy and safety of drugs targeting this specific amyloid region (Source 1.2.3, 1.3.2).

Other names

Amyloid-beta (1-15)Aβ(1-15)N-terminal Aβ epitopeB-cell epitope of Amyloid-betaAmyloid-beta peptide fragment 1-15

Immunotherapy (active and passive) aimed at promoting microglial-mediated clearance of amyloid plaques and neutralizing soluble Aβ oligomers (Source 1.3.2, 1.3.3).